Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

vTv Therapeutics (VTVT) Shares Outstanding (Weighted Average) (2016 - 2025)

vTv Therapeutics' Shares Outstanding (Weighted Average) history spans 11 years, with the latest figure at $8.4 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Weighted Average) rose 45.96% year-over-year to $8.4 million; the TTM value through Dec 2025 reached $8.4 million, up 45.96%, while the annual FY2025 figure was $8.4 million, 45.96% up from the prior year.
  • Shares Outstanding (Weighted Average) for Q4 2025 was $8.4 million at vTv Therapeutics, up from $8.1 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $80.5 million in Q3 2022 and bottomed at $1.6 million in Q4 2021.
  • The 5-year median for Shares Outstanding (Weighted Average) is $6.5 million (2024), against an average of $22.6 million.
  • The largest annual shift saw Shares Outstanding (Weighted Average) crashed 97.41% in 2023 before it surged 207.12% in 2024.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $1.6 million in 2021, then increased by 22.58% to $1.9 million in 2022, then grew by 8.6% to $2.1 million in 2023, then surged by 176.79% to $5.8 million in 2024, then soared by 45.96% to $8.4 million in 2025.
  • Per Business Quant, the three most recent readings for VTVT's Shares Outstanding (Weighted Average) are $8.4 million (Q4 2025), $8.1 million (Q3 2025), and $6.6 million (Q2 2025).